This article was first published in LSIPR, June 2018.

Gregory Bacon has been quoted in this article.

With Brexit looming, questions are being asked about the future regulatory relationship between the EU and the UK, with life sciences companies wondering how they will be affected. LSIPR reports.

The UK’s departure from the EU has been the topic of much sparring and speculation since the controversial vote in June 2016, but one important implication of Brexit has been little discussed in the mainstream news: medicines regulation.

To view the full article, please see the LSIPR website here.